David Dorey

2.2k total citations
10 papers, 156 citations indexed

About

David Dorey is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, David Dorey has authored 10 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 7 papers in Virology and 1 paper in Molecular Biology. Recurrent topics in David Dorey's work include HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (7 papers). David Dorey is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV Research and Treatment (7 papers) and HIV/AIDS Research and Interventions (7 papers). David Dorey collaborates with scholars based in Canada, United States and United Kingdom. David Dorey's co-authors include Sandy Griffith, William Spreen, David M. Margolis, Miranda Murray, Anthony Mills, Robert L. Dobbins, A.P. Sykes, Susan Walker, W. O. Wilkison and Dannae Brown and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes Obesity and Metabolism and AIDS and Behavior.

In The Last Decade

David Dorey

10 papers receiving 151 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Dorey Canada 6 112 74 43 35 24 10 156
Gulam Latiff United States 5 156 1.4× 140 1.9× 37 0.9× 17 0.5× 12 0.5× 9 224
Laura Comi Italy 9 127 1.1× 91 1.2× 39 0.9× 9 0.3× 8 0.3× 29 180
Coca Necsoi Belgium 8 97 0.9× 77 1.0× 40 0.9× 6 0.2× 9 0.4× 23 146
Sara Lino Portugal 5 44 0.4× 32 0.4× 43 1.0× 6 0.2× 14 0.6× 14 98
Christelle Tomei France 4 94 0.8× 47 0.6× 36 0.8× 14 0.4× 7 0.3× 4 147
Cal Cohen United States 8 219 2.0× 158 2.1× 34 0.8× 9 0.3× 10 0.4× 15 260
Hylke Waalewijn Netherlands 4 79 0.7× 41 0.6× 37 0.9× 5 0.1× 8 0.3× 10 116
Anthony Scarsella United States 6 127 1.1× 97 1.3× 33 0.8× 7 0.2× 12 0.5× 7 153
Jorge Vergas Spain 6 78 0.7× 68 0.9× 58 1.3× 3 0.1× 34 1.4× 17 178
Jules Bashi France 6 146 1.3× 49 0.7× 56 1.3× 23 0.7× 2 0.1× 6 177

Countries citing papers authored by David Dorey

Since Specialization
Citations

This map shows the geographic impact of David Dorey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Dorey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Dorey more than expected).

Fields of papers citing papers by David Dorey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Dorey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Dorey. The network helps show where David Dorey may publish in the future.

Co-authorship network of co-authors of David Dorey

This figure shows the co-authorship network connecting the top 25 collaborators of David Dorey. A scholar is included among the top collaborators of David Dorey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Dorey. David Dorey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Han, Kelong, Paul Benn, Jörg Sievers, et al.. (2025). A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV. Clinical Pharmacology in Drug Development. 14(7). 528–541. 1 indexed citations
2.
Wu, Sterling, Feifan Zhang, David Dorey, et al.. (2020). 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Open Forum Infectious Diseases. 7(Supplement_1). S544–S544. 2 indexed citations
3.
Murray, Miranda, Antonio Antela, Anthony Mills, et al.. (2020). Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks. AIDS and Behavior. 24(12). 3533–3544. 53 indexed citations
4.
Chounta, Vasiliki, Enrique Bernal, Johan Lombaard, et al.. (2020). 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. Open Forum Infectious Diseases. 7(Supplement_1). S548–S548. 4 indexed citations
5.
Cutrell, Amy, Ronald D’Amico, David Dorey, et al.. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases. 6(Supplement_2). S20–S20. 4 indexed citations
6.
Murray, Miranda, Federico Pulido, Anthony Mills, et al.. (2019). Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. SHILAP Revista de lepidopterología. 20(4-5). 111–122. 26 indexed citations
7.
Demarest, James F., Mark Underwood, Marty St. Clair, et al.. (2018). Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance. AIDS Research and Human Retroviruses. 34(4). 343–346. 16 indexed citations
8.
Cahn, Pedro, Jaime Andrade‐Villanueva, Carlos Beltrán, et al.. (2015). P032: Dolutegravir versus raltegravir in ARV-experienced INI-naïve HIV+ adults: 48-week subgroup analysis of Latin American subjects in the SAILING study. Journal of the International AIDS Society. 18(3 (Suppl 2)). 9 indexed citations
9.
Sykes, A.P., Robert L. Dobbins, David Dorey, et al.. (2014). Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obesity and Metabolism. 17(1). 94–97. 33 indexed citations
10.
Crush, Jonathan, et al.. (2010). Migration-induced HIV and AIDS in rural Mozambique and Swaziland. Medical Entomology and Zoology. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gulam Latiff Breakdown of academic impact, for papers by Laura Comi Breakdown of academic impact, for papers by Coca Necsoi Breakdown of academic impact, for papers by Sara Lino Breakdown of academic impact, for papers by Christelle Tomei Breakdown of academic impact, for papers by Cal Cohen Breakdown of academic impact, for papers by Hylke Waalewijn Breakdown of academic impact, for papers by Anthony Scarsella Breakdown of academic impact, for papers by Jorge Vergas Breakdown of academic impact, for papers by Jules Bashi
Rankless by CCL
2026